Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Review article

Antiviral potential of natural products from marine microbes

Mengqi Yi, Sixiao Lin, Bin Zhang, Haixiao Jin, Lijian Ding*

Li Dak Sum Yip Yio Chin Kenneth Li Marine Biopharmaceutical Research Center, Department of Marine Pharmacy, College of Food and Pharmaceutical Sciences, Ningbo University, Ningbo, 315832, China

ARTICLE INFO

Article history:
Received 18 July 2020
Received in revised form 25 August 2020
Accepted 26 August 2020
Available online 31 August 2020

Keywords:
Marine microbes
Marine natural products
Antivirus
Anti-influenza
Anti-HSV
Anti-HIV

ABSTRACT

Humans have been suffered from viral infections over the centuries, such as influenza, HSV, and HIV, which have killed millions of people worldwide. However, the availability of effective treatments for infectious diseases remains limited until now, as most of the viral pathogens resisted to many medical treatments. Marine microbes are currently one of the most copious sources of pharmacologically active natural products, which have constantly provided promising antivirus agents. To date, a large number of marine microbial secondary metabolites with antiviral activities have been widely reported. In this review, we have summarized the potential antivirus compounds from marine microorganisms over the last decade. In addition, the structures, bioactivities, and origins of these compounds were discussed as well.

© 2020 Elsevier Masson SAS. All rights reserved.

Contents

1. Introduction ................................................... 1
2. Potential anti-virus agents from marine microbes ................................................................. 2
  2.1. Anti-influenza virus compounds .......................................................... 2
  2.2. Anti-HSV virus compounds ............................................................ 5
  2.3. Others including HIV, HCV, RSV, EV71, DENV, CHIKV, and WEEV antivirals .................................................. 7
3. Conclusions ..................................................... 9
Declaration of competing interest ................................................................. 9
Acknowledgments .................................................................................. 9
References ............................................................................................. 9

1. Introduction

As we all know, viral infections are the main reasons for human death worldwide [1]. Several infectious viral diseases occurred so far have been reported, which involve viruses such as influenza [2], Herpes Simplex Virus (HSV) [3], Human Immunodeficiency Virus (HIV) [4], Respiratory Syncytial Virus (RSV) [5], Enterovirus 71 (EV71) [6], Dengue Virus (DENV) [7], Ebola Virus [8], as well as the recently emerging coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [9]. The main characteristic of viruses is that their genomes are easily mutated, making it difficult to control viral infections and causing pandemics worldwide. Meanwhile, in the absence of vaccines and antiviral therapies, the rapid spread of the virus has been accelerated by increased migration, global travel and urbanization [10]. However, most antiviral drugs today have adverse drug reactions and develop viral resistance to treatments. The threat of drug resistance not only results in huge challenges to the clinical
management of viral infections, but also places a heavy burden on the global economy [11]. Although considerable progress has been made in the development of antiviral drugs since acyclovir, a nucleoside analogue, was invented in 1960, novel drugs that can work through different mechanisms to combat resistance are still desperately in need [12]. In recent years, with the development of virology, many virus-specific processes or proteins have been identified as targets for chemotherapy [13]. Viral replication cycle includes viral adsorption, viral cell fusion, reverse transcription, integration, translation and other steps, which can be used as targets for antiviral drugs [14]. In addition, specific viral enzymes which involve the synthesis of viral DNA, RNA and glycoproteins are also potential targets [15]. For example, acyclovir disturbs some key herpes virus enzymes that have an affinity for nucleotide analogues [16]. Despite the successful understanding of viral proliferation cycle and comprehensive studies for suitable vaccines and treatments against viral infections over the past half of century, still several infections such as HIV afflict a substantial proportion of the world populations in all generations [17]. There is no definite vaccine against numerous prevalent viral infections, including most respiratory-tract viruses, HSV-1 and HSV-2 or DEVN [18]. Moreover, drug resistance to available antiviral agents by different viruses such as the HIV type 1 or HSV-1 has always been a serious impediment to treatment of viral infections, stimulating the search for new effective molecules [16,17].

Recently, the ocean has arisen great attention from scholars and practitioners, as many marine derived secondary metabolites with evidently anti-inflammatory, antitumor, antimicrobial, antiviral, antimalarial, and antioxidant activities have been discovered [19,20]. According to the MarinLit database, annually more than 1200 novel natural products were reported from a variety of marine sources, such as algae, corals, sponges, and especially microorganisms [19]. Moreover, these antiviral natural compounds even have entered the advanced stages of clinical trials, several of which are commercially available. For example, vidarabine is currently used for the treatment of HSV infection, whose lead structure, spongouridine, was originally isolated from the marine sponge [21]. Marine microorganisms have become a promising reservoir of new antiviral secondary metabolites [22]. There are about 1 million microorganisms in 1 mL of seawater, including some cyanobacteria, actinomycyes, bacteria, and fungi, which have great potential in the pharmaceutical research [23]. In addition, some of marine microorganisms rely on the symbiosis with marine animals and plants to acquire nutrition, but due to fierce competition, they have metabolized some specific molecules to obtain extremely limited resources [24]. These secondary metabolites can chemically be divided into alkaloids, peptides, polyketides, terpenoids, etc, which contained diverse biological functions such as antibacterial, antiviral and antitumor activities. Excitingly, cyanobacterial-derived cyanovirin N has been utilized as anti-HIV compound in preclinical development [25]. However, only limited natural compounds discovered from marine microbes have been used in clinical research, reflecting the lack of understanding and development of marine microbial resources [26].

This review provided a comprehensive overview of 79 natural products derived from marine microbes over the last decade, presenting various antiviral activities, including anti-influenza (48%) anti-HSV (33%), and others (19%) (Fig. 1). These secondary metabolites were mainly isolated from marine microbes Aspergillus, Penicillium and Streptomyces discovered from the marine environment of different countries (Figs. 2 and 3). Most of antiviral molecules were obtained from marine microbes sampled in China. 18 secondary metabolites, such as truncateol O (16) and R-wailupemycin K (18), displayed significant antiviral activities even more effective than those of the positive drugs [27,28]. Table 1, Table 2 and Table 3 listed the name, isolation source (marine microbes) and the antiviral activities of these compounds.

2. Potential anti-virus agents from marine microbes

2.1. Anti-influenza virus compounds

Among human influenza viruses, influenza A virus is the most susceptible to mutations causing worldwide pandemics many times, such as 1918 Spanish flu pandemic [29]. Influenza viruses contain two functional surface glycoproteins: hemagglutinin (HA) and neuraminidase (NA) [30]. NA has become a major target for drug design against influenza virus as it acts as a significant role in influenza virus replication and has highly protected active site [31,32]. Rubrolide S (Fig. 4), a new rubrolide, was first discovered in the fermentation broth of the marine-derived fungus Aspergillus terreus OUCMDZ-1925 that was isolated in vescera of the barracuda (Chelon haematocheilus) grown in the Yellow River [33]. This compound displayed significant inhibitory activity toward H1N1 virus with IC50 value of 87.1 μM (ribavirin as positive control, IC50 = 118.8 μM) [33]. Chemical study of marine-derived Streptomyces youssoufienis OUC6819 discovered that heterologous expression of the type III polyketide synthase (PKS) gene via resulted in production of four novel violapyrones (VLPs), VLPs Q–T (2–5, Fig. 4) [34]. Using ribavirin as a positive control, anti-influenza A [H1N1 (A/Virginia/ATCC1/2009) and H3N2 (A/Alchi/2/1968)] virus activity of VLPs were evaluated [34]. The results showed that these VLPs exhibited considerable anti-H1N1 and anti-H3N2 activities with IC50 Values of 30.6–68.4 μM and 45.3–95.0 μM, respectively (ribavirin as positive control, IC50 = 66.7 and 99.6 μM, respectively) [34]. The strain Cladosporium sphaerospermum 2005-01-E3, isolated from sediments collected in the Pacific Ocean, resulted in the isolation of a new hybrid polyketide, cladosin C (6, Fig. 4) [35]. Compound 6 exhibited anti-influenza A H1N1 virus activity with IC50 value of 276 μM (ribavirin as positive control, IC50 = 131 μM) [35]. Another marine fungus Penicillium chrysogenum PXJ-17 was derived from a soft coral collected at Terra Nova Bay, Antarctica. Chemical investigation of the fungus P. chrysogenum PXJ-17 afforded two novel sorbicillinoids combining a bicycle [2.2.2] octane with a 2-methoxyphenol moiety, named spongouridine, was originally isolated from the marine sponge [21]. Marine microbes have become a promising reservoir of new antiviral secondary metabolites [22]. There are about 1 million microorganisms in 1 mL of seawater, including some cyanobacteria, actinomycyes, bacteria, and fungi, which have great potential in the pharmaceutical research [23]. In addition, some of marine microorganisms rely on the symbiosis with marine animals and plants to acquire nutrition, but due to fierce competition, they have metabolized some specific molecules to obtain extremely limited resources [24]. These secondary metabolites can chemically be divided into alkaloids, peptides, polyketides, terpenoids, etc, which contained diverse biological functions such as antibacterial, antiviral and antitumor activities. Excitingly, cyanobacterial-derived cyanovirin N has been utilized as anti-HIV compound in preclinical development [25]. However, only limited natural compounds discovered from marine microbes have been used in clinical research, reflecting the lack of understanding and development of marine microbial resources [26].
isomers (13 and 14) into the active sites of NA showed that the E double bond was essential to achieve activity [38]. Anthranoside C (15, Fig. 5) was purified from the marine sponge-derived Streptomyces sp. CMN-62 collected from Naozhou Island of the Guangdong Province, China [39]. This compound exhibited inhibitory activity against H1N1 with IC50 value of 171 μM (ribavirin as positive control, IC50 = 133 μM) [39].

Chemical investigation of the extract of sponge-associated fungus Truncatella angustata XSB-01-43 isolated from a finger sponge Amphimedon sp. collected from the reef at a depth of 10 m in Yongxing Island, Hainan Province of China, in June 2012, resulted in the isolation of truncatol O (16, Fig. 6) [27]. Compound 16 showed anti-H1N1 activity with IC50 value of 30.4 μM, which was stronger than that of oseltamivir (OSV), a positive control with IC50 value of 46.7 μM [27]. The marine sponge-derived Streptomyces sp. CMN-62 was associated with the marine green algae E. prolifera, and produced three new phenolic polyketides, wailupemycin J (17, Fig. 6), R-wailupemycin K (18, Fig. 6), deoxyenterocin (19, Fig. 6) [28]. It was first reported that compounds 17, 18, and 19 displayed comparable anti-H1N1 activity with 47.8%, 42.5% and 60.6% inhibitions, respectively at 50 μg/mL, while the positive control, ribavirin, with the inhibition rates of 45.3% at the same concentration [28]. Two new meroterpenoids, chrodrimanins K (20, Fig. 6) and N (21, Fig. 6), as well as the known 3-hydroxypentacecilide A (22, Fig. 6) were separated from the fermentation broth of Penicillium sp. SCS-KFD09, which was gathered from a marine worm, Sipunculus nudus, from Haikou Bay, China [40]. Compounds 20, 21, and 22 exhibited inhibitory activity against H1N1 virus with IC50 values of 74, 58, and 34 μM, respectively (ribavirin as positive control, IC50 = 103 μM) [40]. The Aspergillus sp. SCSIO XWS02F40 derived from a marine sponge resulted in the discovery of two new asteltoxins named asteltoxins E (23, Fig. 6) and F (24, Fig. 6) [41]. These compounds were shown to have significant anti-H1N1 activities with IC50 values of 6.2 ± 0.08 and 8.9 ± 0.3 μM, respectively. Additionally, compound 23 also showed inhibitory activity against H1N1 with IC50 value of 3.5 ± 1.3 μM [41]. Oseltamivir was used as the positive control with IC50 values of 18.5 and 16.9 nM, respectively [41]. A new compound named 6-O-demethylmonocerin (25, Fig. 6) and a known analogue, (+)-monocerin (26, Fig. 6), were obtained from marine Aspergillus sp. OUCMDZ-1583, and collected from the Xisha Islands of China [42]. Compounds 25 and 26 showed anti-H1N1 activity with IC50 values of 172.4 and 175.5 μM, respectively (ribavirin as positive control, IC50 = 137.3 μM) [42].

Five new indole-diterpenoids (27–31, Fig. 7), were collected from the fermentation broth of Penicillium camemberti OUCMDZ-1492 that was isolated from an acidic marine niche, mangrove soil and mud, around the roots of Rhizophora apiculata at pH 5.0, together with emindole SB (32, Fig. 7), 21-isopentenylpaxilline (33, Fig. 7). The percentage of antiviral compounds isolated from marine microbes according to anti-virus types.

Fig. 1. The percentage of antiviral compounds isolated from marine microbes according to anti-virus types.

Fig. 2. The number of antiviral compounds isolated from marine microbes according to genera and sampling sources.

Fig. 3. Marine microbial sampling sites for new and known antiviral compounds reported from 2009 to 2019.
A marine-derived fungal strain, *Aspergillus terreus*, 
crease the anti-H1N1 activity of hexacyclic indole-diterpenoids [43].

Table 1

| Metabolites                  | Species                  | Activities                  | Ref  |
|------------------------------|--------------------------|-----------------------------|------|
| Rubrolide S (1)              | *A. terreus* OUCMDZ-1925.| IC₅₀ = 87.1 µM (H₁N₁ virus). | [33] |
| VLPs Q–T (2–5)               | *S. yousoufisensis* OUC6819 | IC₅₀ = 30.6–68.4 µM, resp. (H₁N₁ virus) IC₅₀ = 45.3–95.0 µM, resp. (H₂N₂ virus) | [34] |
| Cladosin C (6)               | *C. sphaerospermum* 2005-01-E3 | IC₅₀ = 276 µM (H₁N₁ virus) | [35] |
| Sorbicatcheol A (7), B (8)   | *P. chrysogenum* PJX-17 | IC₅₀ = 85 and 113 µM, resp. (H₁N₁ virus) | [36] |
| (3Z,6E)-3-(4-hydroxybenzylidene)-6-isobutylideneperiperae-2,5-dione (9) (3Z,6S)-3-benzylidene-6-isobutylideneperiperae-2,5-dione (10) Albonauris (11) | Streptomyces sp. PFX7328 | IC₅₀ = 41.5 ± 4.5, 28.9 ± 2.2 and 6.8 ± 1.5 µM, resp. (H₁N₁ virus) | [37] |
| Isoaspinuline E (12)         | *A. terreus* Gwq-48 | IC₅₀ = 32.3, 56.9, and 29.1 µg/mL, resp. (H₁N₁ virus) | [38] |
| Aspunuline E (13)            | Streptomyces sp. CMN-62 | IC₅₀ = 171 µM (H₁N₁ virus) | [39] |
| Pulic acid (14)              | T. angustata XSB-01-43 | IC₅₀ = 30.4 µM (H₁N₁ virus) | [27] |
| Anthranoside C (15)          | Streptomyces sp. OUCMDZ-3434 | IC₅₀ = 47.8%, 42.5% and 60.6% inhibitions at 50 µg/mL, resp. (H₁N₁ virus) | [28] |
| Truncateol O (16)            | Penicillium sp. SCS-KF09 | IC₅₀ = 74, 58, and 34 µM, resp. (H₁N₁ virus) | [40] |
| Wailupemycin J (17)          | Aspergillus sp. SCSIO XWS2F40 | IC₅₀ = 3.5 ± 1.3 µM (H₁N₁ virus) | [41] |
| R-wailupemycin K (18)        | Aspergillus sp. SCSIO 1583 | IC₅₀ = 172.4 and 175.5 µM, resp. (H₁N₁ virus) | [42] |
| Deoxytentericin (19)         | Aspergillus sp. OUCMDZ-1925 | IC₅₀ = 74.2 and 0.41 µM, resp. (H₁N₁ and H₂N₂ virus) | [44] |
| Chrodrimanin K (20) N (21)   | *P. canemberti* OUCMDZ-1492 | IC₅₀ = 28.3, 38.9, 32.2, 73.3, 34.1, 26.2, 66, 77.9, and 177 µM, resp. (H₁N₁ virus) | [43] |
| 3-Hydroxypentaclecide A (22) | *A. terreus* SCSGAF0162 | IC₅₀ = 20.2 and 0.41 µM, resp. (H₁N₁ and H₂N₂ virus) | [44] |
| 6-O-demethylmonocerin (25)   | Chladorocarpus sp. SCSI0001 | IC₅₀ = 16.2 µM (H₂N₂ virus) | [45] |
| (±)-Monocerin (26)           | *A. terreus* SCSGAF0162 | IC₅₀ = 17.0 µM (H₁N₁ virus) | [46] |

Table 2

| Metabolites                  | Species                  | Activities                  | Ref  |
|------------------------------|--------------------------|-----------------------------|------|
| (45)-10-hydroxy-10-methyl-11-oxo-dodec-2-en-1,4-olide (39) | *S. koyangensis* | EC₅₀ = 25.4 µM (HSV-1 virus) | [53] |
| Simpliciliumtrite J (40)     | *S. obclavatum* | IC₅₀ = 14.0, 16.7, and 15.6 µM, resp. (HSV-1 virus) | [54] |
| Verlamine A (41) B (42)      | *A. vernicolor* SCSIO 41502 | IC₅₀ = 4.68, 6.25, and 3.12 µM, resp. (HSV-1 virus) | [55] |
| Aspergillus H (43), I (44)   | *T. effusa* DFFSCS021 | IC₅₀ = 3.08, 9.37, and 3.12 µM, resp. (HSV-1 virus) | [56] |
| Cocconquinone A (45)         | *A. terreus* SCSGAF0162 | IC₅₀ = 16, 8.7, and 14 µM, resp. (HSV-1 virus) | [57] |
| Trichobrysin A (46), B (47), D (48) | *A. terreus* SCSGAF0162 | IC₅₀ = 9.5 and 19.8 µM, resp. (HSV-1 virus) | [58] |
| Acromoneptides A (49), B (50) Al(III)-acromoneptide D | *A. terreus* SCSGAF0162 | IC₅₀ = 16.4 ± 0.6, 6.34 ± 0.4, 21.8 ± 0.8 and 28.9 ± 0.8 µg/mL, resp. (HSV-1 virus) | [59] |
| Aspergillicepptides D (52), E (53) | *A. terreus* SCSGAF0162 | IC₅₀ = 0.45 µM (HSV-1 virus) | [60] |
| 12z-Dehydroxysterioresinactone A (54) | *A. terreus* SCSGAF0162 | IC₅₀ = 1, 1, 0.1, 0.01, 0.1 µg/mL, resp. (HSV-1 virus) | [61] |

Fig. 7, and paspaline [34, Fig. 7], paspaline [35, Fig. 7] [43]. When compared with ribavirin ([IC₅₀ = 113.1 µM]), compounds 27–35 displayed significant activities against influenza virus A (H₁N₁ virus) with IC₅₀ values of 28.3, 38.9, 32.2, 73.3, 34.1, 26.2, 66, 77.9, and 177 µM, respectively [43]. Moreover, the results showed that 3-oxo,4-hydroxy, and 9-isopentenyl substitutions tended to increase the anti-H₁N₁ activity of hexacyclic indole-diterpenoids [43]. A marine-derived fungal strain, *Aspergillus terreus* SCSGAF0162, was isolated from the tissue of the gorgonian *Echinogorgia aurantiaca* collected from Sanya, Hainan Province, China [44]. Asperterrestide A (36, Fig. 7), a new alkaloid purified from the fermentation broth of the *A. terreus* SCSGAF0162, had a rare 3-OH-N-CH₃-Phe residue and exhibited inhibitory activity against H₁N₁ and H₂N₂ virus with IC₅₀ values of 15 and 8.1 µM, respectively (ribavirin as positive control, IC₅₀ = 20.2 and 0.41 µM, respectively) [44].
Cladosporisteroid B (37, Fig. 8) was a new highly oxygenated sterol that was obtained from the extracts of the culture of a sponge-derived fungus *Cladosporium* sp. SCSIO41007 collected from the sea area near Xuwen County, Guangdong Province, China [45]. Compound 37 showed weak anti-H3N2 activity with IC50 value of 16.2 μM (IC50 = 34.0 nM for the positive control oseltamivir) [45].

The fungal strain *Aspergillus ochraceus* Jcma1F17 was isolated from a marine algae *Coelarthrum* sp. collected in Paracel Islands, South China Sea, which produced a new nitrobenzoyl sesquiterpenoid, 6β,9α-dihydroxy-14-p-nitrobenzoylcinnamolide (38, Fig. 8) [46]. Nitrobenzoyl sesquiterpenoids are rare in natural sources, and *Aspergillus* species are the only sources of them. Compound 38 showed inhibitory activity against H3N2 with IC50 value of 17.0 μM (oseltamivir as positive control, IC50 = 0.008 μM) [46].

### 2.2. Anti-HSV virus compounds

HSV-1 is regularly correlative to oral-facial infections and encephalitis, whereas HSV-2 frequently causes genital ulcers worldwide [47,48]. Herpes virus has a unique incubation period and physiological reactivation characteristics [49]. The chronic incubation period makes the host susceptible to repeated attacks by virus activation and increases the possibility of virus transmission [50]. At present, clinically effective anti-herpes virus drugs such as acyclovir, valacyclovir and other nucleoside analogues are mainly used as nucleoside inhibitors of DNA polymerase [51]. However, due to antiherpetic drugs resistance and lack of validated vaccines for effective prevention, it is urgent to develop novel medicines against HSV virus [52]. A strain of marine-derived *Streptomyces koyangensis* SCSIO 5802, which was isolated from the South China Sea area, produced a new trien-7-one (67) that showed inhibitory activity against HSV-1 with IC50 value of 7.7 μM (HCV virus) [66].

### Table 3

| Metabolites                        | Species               | Activities                                              | Ref  |
|-----------------------------------|-----------------------|---------------------------------------------------------|------|
| Truncateols O (2), P (65)         | *T. angustata*        | IC50 = 39.0 and 16.1 μM, resp. (HIV virus)              | [27] |
| Trypilpyrazinol (66)              | *Penicillium* sp. IMB17-046 | IC50 = 4.6 and 3.5 μM, resp. (HIV-1 virus)             | [66] |
| 3β-hydroxyergosta-8,14,24(28)-trien-7-one (67) | *A. niger* SCSIO Jcsw6F30 | IC50 = 7.7 μM (HCV virus)                               | [67] |
| Aspernigrin C (68)                | *Aspergillus* sp. IMB17-046 | IC50 = 34.0 nM (HIV-1 virus)                            | [45] |
| Malformin C (69)                 | *Cladosporium* sp. WZ-2008-0042 | IC50 = 0.12 mM (RSV virus)                              | [70] |
| Cytosporin L (71)                | *Eustepella* sp.      | IC50 = 72.01 and 30.25 μM, resp. (RSV virus)           | [71] |
| Cytosporin D (72)                | *P. chrysogenum* SCSIO 41001 | IC50 = 14.5 μM (EV71 virus)                             | [74] |
| 3α,5β-dihydroxy-14-p-nitrobenzoylcinnamolide (38) | *A. ochraceus* Jcma1F17 | IC50 = 9.4 μM (EV71 virus)                             | [46] |
| ZSU-HBS A (74)                   | *Trichoderma* sp. SCSIO41004 | IC50 = 25.7 μM (EV71 virus)                             | [75] |
| Scequinadoline A (75)            | *D. cepii* F31-1      | IC50 = 72.01 and 30.25 μM, resp. (RSV virus)           | [71] |
| Debromaplysiatoxin (76)          | *Trichoderma* sp.     | IC50 = 4.7 ± 0.4 and 1.4 ± 0.06 μM, resp. (HIV-1 virus) | [67] |
| 3-Methoxydebromaplysiatoxin (77) | *A. ochraceus*        | IC50 = 9.4 μM (EV71 virus)                             | [46] |
| Antimycin A10α (79)              | *S. kaviengensis*     | IC50 = 3 nM (WEEV virus)                               | [81] |

*Aspergillus* species are the only sources of them. Compound 38 showed inhibitory activity against H3N2 with IC50 value of 17.0 μM (oseltamivir as positive control, IC50 = 0.008 μM) [46].
Sea at a depth of 3536 m, resulted in the discovery of a novel butenolide derivative, (4S)-10-hydroxy-10-methyl-11-oxo-dodec-2-en-1,4-olide (39, Fig. 9) featuring octyl substitution at γ-position [53]. The new compound 39, displayed anti-HSV-1 activity with EC50 value of 25.4 μM (Ganciclovir as positive control, EC50 = 0.025 μM) [53]. Xiao Liang et al. separated simplicilliumtide J (40, Fig. 9), and verlamelins A and B (41, 42, Fig. 9) from the deep-sea-derived fungal strain Simplicillium obclavatum EIODSF 020 [54]. These compounds displayed significant anti-HSV-1 activity with IC50 values of 14.0, 16.7, and 15.6 μM, respectively (acyclovir as positive control, IC50 = 3.5 μM). This is the first time to report the antiviral activity of these cyclic peptides [54].

Two new anthraquinones, aspergilols H, I (43, 44, Fig. 9) and coccoquinone A (45, Fig. 9) were purified from the deep-sea-associated fungus Aspergillus versicolor SCSIO 41502, collected from marine sediment sample at a depth of 2326 m from the South China Sea [55]. These compounds displayed significant antiviral activity towards HSV-1 with EC50 values of 4.68, 6.25, and 3.12 μM, respectively (acyclovir as positive control, EC50 = 3.0 μM) [55].

Chemical investigation of the culture of Trichobotrys effuse DFFSC021 that was isolated from the deep sea sediment collected from the South China Sea, resulted in the isolation of three new tetramic acid derivatives with a decalin ring, trichobotrysins A, B and D (46–48, Fig. 10) [56]. Compounds 46–48 possessed evidently anti-HSV-1 activity with IC50 values of 3.08, 9.37, and 3.12 μM (acyclovir as positive control, IC50 = 3.5 μM). This is the first time to report the anti-HSV-1 activity of this type of compounds [56]. Minghe Luo et al. separated two novel hydroxamate-containing natural product cyclopeptides designated acremonpeptides A (49, Fig. 10) and B (50, Fig. 10), along with Al(III)–acremonpeptide D (51, Fig. 10) from the extract of the fungal strain Acremonium persicinum SCSIO 115, which was isolated from a marine sediment sample collected in the South China Sea [57]. These compounds in vitro exhibited moderate antiviral activities for HSV-1 with EC50 values of 16, 8.7, and 14 μM, respectively [57]. A gorgonian sample collected from the South China Sea, Sanya, Hainan Province, resulted in the isolation of Aspergillus sp. SCSIO 41501, which further led to the isolation of two new linear peptides, namely, aspergillipesptides D and E (52, 53, Fig. 10) [58]. Compounds 52 and 53 exhibited evidently inhibition against herpes simplex virus type 1 (HSV-1) with IC50 values of 9.5 and 19.8 μM under their non-cytotoxic concentrations against a Vero cell line, respectively [58]. Additionally, compound 53 also had antiviral activity against acyclovir-resistant clinical isolates of HSV-1 [58].

Xu-Hua Nong et al. separated eight territrem derivatives along with nine butyrolactone derivatives from a marine-derived fungus Aspergillus terreus SCSCG0162 under rice solid-state fermentation, which was gathered from South China Sea gorgonian coral Echinogorgia aurantiaca [59]. All the isolated metabolites were evaluated for anti-HSV-1 activities, only 12α-dehydroxyisoterreulactone A (54, Fig. 11), arisugacin A (55, Fig. 11), isobutyrolactone II (56, Fig. 11), and aspernolide A (57, Fig. 11) were shown to have obviously inhibitory effects with IC50 values of 16.4 ± 0.6, 6.34 ± 0.4, 21.8 ± 0.8 and 28.9 ± 0.8 μg/mL, respectively [59]. Balticolid (58, Fig. 11)
Fig. 11, a novel 12-membered macrolide, was separated from the extraction of the culture broth of the fungal strain 222 belonging to the Ascomycota, which was found in driftwood collected from the coast of the Greifswalder Bodden, Baltic Sea, Germany [60]. This compound exhibited antiviral activity against HSV-1 with IC$_{50}$ value of 0.45 μM [60].

Another study on the same fungal strain 222 resulted in the discovery of six novel naphthalenone derivatives, balticols A–F (59–64, Fig. 12) [61]. The balticols were tested at non-cytotoxic concentrations for their antiviral activity against Herpes simplex virus (HSV) type I. These compounds were found to showed inhibitory effect with IC$_{50}$ values of 1, 1, 0.1, 0.01, 0.1 μg/mL, respectively [61]. Balticol E had the most remarkable result with IC$_{50}$ value of 0.01 μg/mL against HSV-1 [61].

2.3. Others including HIV, HCV, RSV, EV71, DENV, CHIKV, and WEEV antivirals

HIV-1 and HIV-2 can infect human beings and cause severe immunosuppression through decline of CD4$^+$ cells [62,63]. So far, over 30 antiretroviral drugs were on the market for the treatment of HIV infection and divided into six main groups: integrase inhibitors, protease inhibitors, non-nucleoside reverse transcriptase inhibitors, nucleoside/nucleotide reverse transcriptase inhibitors, and entry inhibitors [64]. However, in the United States, the annual cost of the drugs per individual can be as high as $24,000 relying on the types of anti-HIV medicines [65]. Two undescribed isoprenylated, truncateols O (2, Fig. 6) and P (65, Fig. 13) were collected from the sponge-derived fungus Truncatella angustata [27]. Compounds 2 and 65 showed anti-HIV effects by blocking HIV replication in one-cycle infection assay with IC$_{50}$ values of 39.0 and 16.1 μM, respectively [27]. Moreover, though efavirenz (positive control) displaying stronger activity than the data raising from the isolated compounds, the lower cytotoxicity of the collected compounds (IC$_{50} > 100$ μM) in comparison with efavirenz (IC$_{50} = 40.6$ μM) suggested that these compounds were worthy for further observation as anti-HIV leads [27]. Chemical investigation of the extract of marine-derived fungus Penicillium sp. IMB17-046 isolated from marine sediments collected from a mangrove swamp in Sanya, Hainan province, China, resulted in the isolation of trypilpyrazinol (66, Fig. 13) and 3β-hydroxyergosta-8,14,24(28)-
These compounds exhibited broad-spectrum inhibitory activities against different types of viruses, including human immunodeficiency virus (HIV), and hepatitis C virus (HCV) [66]. Compound 66 showed inhibitory activities against HIV-1 and HCV with IC50 values of 4.6 and 7.7 μM, respectively. Compound 67 displayed anti-HIV-1 activity with IC50 value of 3.5 μM [66]. The marine derived Aspergillus niger SCSIO Jcsw6F30 was associated with a marine algae Sargassum sp. collected in Yongxing Island, South China Sea, in July 2012, and produced a novel 2-benzylpyridin-4-one containing metabolite, aspernigrin C (68, Fig. 13) and malformin C (69, Fig. 13) [67]. These compounds exhibited obvious anti-HIV-1 activities with IC50 values of 4.7 ± 0.4, 1.4 ± 0.06 μM, respectively (abacavir as a positive control, IC50 = 0.8 ± 0.1 μM) [67].

RSV is considered to be the major pediatric respiratory pathogen, triggered by G protein combining host cell receptors [68]. Only limited therapeutic compounds for RSV have been reported, such as paclizumab and ribavirin, accounting for the urgency to develop novel anti-RSV drugs [68,69]. Meilin Yu et al. separated a new pregnane D(7, Fig. 14) and malformin C (69, Fig. 13) [67]. These compounds exhibited obvious anti-HIV-1 activities with IC50 values of 4.7 ± 0.4, 1.4 ± 0.06 μM, respectively (abacavir as a positive control, IC50 = 0.8 ± 0.1 μM) [67].

EV71 viruses can cause acute neurological disease in children, leading to heart and lung failure [72]. Despite broad research with extensive target-based chemical design, developing drugs has failed to meet pharmacological expectations [73]. Another study focused on a deep-sea-derived fungus Penicillium chrysogenum SCSIO 41001, which produced a cinetin dimer named penicitrinone F (73, Fig. 15) [74]. Using the CPE inhibition assay in accordance with protocols, this compound was evaluated for anti-EV71 activity, which exhibited moderate antivirus activity against EV71 with IC50 value of 14.5 μM (ribavirin as positive control, IC50 = 13.3 μM) [74]. Wei Fang et al. isolated a novel nitrobenzoyl sesquiterpenoid 65,8a-dihydroxy-14-p-nitrobenzoylaminolide (38, Fig. 8) collected from the extracts of the culture of marine-derived fungus Aspergillus ochraceus [74, Fig. 15]. This compound displayed anti-EV71 activity with IC50 value of 9.4 μM [46]. Ribavirin was used as the positive control against EV71 virus with IC50 value of 0.6 μM [46]. Chemical study of the extract of sponge-derived fungus Trichoderma sp. SCSIO4100/4 isolated from a Callyspongia sp. sponge collected from the sea area near Xuwen County, Guangdong Province, China, resulted in the isolation of ZSU-H85 A (74, Fig. 15) [75]. Compound 74 was tested for antivirus activity against EV71 on Vero cells, showing anti-EV71 effect with IC50 value of 25.7 μM (IC50 = 13.3 μM) for the positive control ribavirin) [75].

DENV is considered as an urban disease, completing its cycle in humans by the biting of mosquito [76]. Currently, it is vital to develop new antivirus drugs due to the absence of proper treatment or vaccination for DENF [76]. A known fumiquinozaline, scequindolamine A (75, Fig. 16), was obtained from the marine-derived fungus Dichotomomyces cepii F31-1 isolated from the inner tissue of the soft coral Lobophytum crassum which was acquired from Hainan Sanya National Coral Reef Reserve, China [77]. Compound 75 exerted obvious antivirus activity with 50% inhibition at 50 μM against dengue virus serotype 2 productions by standard plaque assay, equivalent to the positive control andrographlide at the same concentration, showing the potential for further development as a dengue virus inhibitor [77].

Chikungunya Virus (CHIKV) is a mosquito-transmitted Alphavirus that has been spreading rapidly, causing more than one million people infected. Although over-the-counter anti-inflammatory drugs can alleviate the symptoms, currently, there is no therapy to cure this disease [78]. Debromoaclavatuxin (76, Fig. 17) and anhydredebromoaclavatuxin (77, Fig. 17), and a new analogue, 3-methoxydebromoaclavatuxin (78, Fig. 17) were purified from the bioactive organic extracts of Trichodesmium erythraeum (TTL/PSK/001), collected from Pulau Seringat Kias, Singapore [79]. Compounds 76, 77 and 78 exhibited significant dose-dependent inhibition of CHIKV in post-treatment, with IC50 values of 1.3, 22.3 and 2.7 μM, respectively [79]. The antiviral mechanisms of these compounds probably targeted a step in the CHIKV replication cycle which occurred after viral entry. Compounds 76 and 78 may represent a new class of antiviral drugs, and further studies of essential pharmacophores probably produce modified leads with improved pharmacological properties [79].
remains an unsolved challenge for antivirus therapy [63]. With the increasing numbers of discovering novel types of viruses and drug resistant strains, it is urgent to develop new antiviral lead agents continuously. During the last decade, 79 marine microbes-derived natural products with 9 types of antivirus activities (anti-influenza, anti-HIV, anti-HCV, anti-RSV, anti-EV71, anti-DENV, anti-CHIKV, and anti-WEEV) were reported (Fig. 1), of which 40 compounds exhibited marked antiviral activities. Intriguingly, 18 compounds, rubrolide S (1), VLPs Q–T (2–5), (3Z,6S)-3-benzylidene-6-isobutylpiperazine-2,5-dione (10), albonoursin (11), truncateol O (16), R-wailupemycin K (18), chodrinamins K and N (20–21), 3-hydroxypentacetilide A (22), astetoxtins E and F (23–24), asperterestide A (36), trichobotorvins A (46) and D (48), and baltico E (63) displayed antivirus activities even stronger than the corresponding positive drugs. However, even if many in vitro studies showed promising results on these compounds, a limited account of in vivo studies has been performed to date. Statistically, these marine microbial compounds with antiviral activities were collected from different marine sources, including sediments, seawaters, algae, sponges, corals, worms as well as gorgonians (Fig. 2). It is notable that over half of these compounds were isolated from marine sediments (50.6%). Marine Aspergillus (24.1%), Penicillium (21.5%) and Streptomyces (16.5%) were recognized as the dominant genera to produce these antiviral natural products (Fig. 2). Collectively, reasonable pharmacological screening of these compounds will offer promising leads for the development of antiviral medicines or antiviral adjuvants. However, so far only Ara-A derived from marine with anti-HSV activity has entered the market and few marine-derived compounds have reached the clinical trials. In the context of the global spread of COVID-19, it is necessary to continue research on novel antiviral natural products in the ocean, especially marine microbes. The marine environment is recognized as a unique but currently under-exploited resource in regard to identifying new compounds as potential therapeutic drugs. These compounds derived from the ocean may possess antiviral activity with unique mechanisms of action. Using chemosynthesis and biosynthesis strategies, it is possible to bring these antiviral natural products into further clinical development. Additionally, a multidisciplinary method that comprised of genomics, metabolomics, microbiology, natural products chemistry, and pharmacology may enrich the pipeline of novel antiviral drugs development with potential lead compounds, which will conduct to a worldwide search for clinically antivirus molecules.

### 3. Conclusions

Many epidemics broke out over the centuries, which have killed millions of people. Nevertheless, few treatments are available for deadly virus infectious diseases till now. Additionally, a great large of antiviral drugs have been described with viral resistance, which remains an unsolved challenge for antivirus therapy [63]. With increasing numbers of discovering novel types of viruses and drug resistant strains, it is urgent to develop new antiviral lead agents continuously. During the last decade, 79 marine microbes-derived natural products with 9 types of antivirus activities (anti-influenza, anti-HIV, anti-HCV, anti-RSV, anti-EV71, anti-DENV, anti-CHIKV, and anti-WEEV) were reported (Fig. 1), of which 40 compounds exhibited marked antiviral activities. Intriguingly, 18 compounds, rubrolide S (1), VLPs Q–T (2–5), (3Z,6S)-3-benzylidene-6-isobutylpiperazine-2,5-dione (10), albonoursin (11), truncateol O (16), R-wailupemycin K (18), chodrinamins K and N (20–21), 3-hydroxypentacetilide A (22), astetoxtins E and F (23–24), asperterestide A (36), trichobotorvins A (46) and D (48), and baltico E (63) displayed antivirus activities even stronger than the corresponding positive drugs. However, even if many in vitro studies showed promising results on these compounds, a limited account of in vivo studies has been performed to date. Statistically, these marine microbial compounds with antiviral activities were collected from different marine sources, including sediments, seawaters, algae, sponges, corals, worms as well as gorgonians (Fig. 2). It is notable that over half of these compounds were isolated from marine sediments (50.6%). Marine Aspergillus (24.1%), Penicillium (21.5%) and Streptomyces (16.5%) were recognized as the dominant genera to produce these antiviral natural products (Fig. 2). Collectively, reasonable pharmacological screening of these compounds will offer promising leads for the development of antiviral medicines or antiviral adjuvants. However, so far only Ara-A derived from marine with anti-HSV activity has entered the market and few marine-derived compounds have reached the clinical trials. In the context of the global spread of COVID-19, it is necessary to continue research on novel antiviral natural products in the ocean, especially marine microbes. The marine environment is recognized as a unique but currently under-exploited resource in regard to identifying new compounds as potential therapeutic drugs. These compounds derived from the ocean may possess antiviral activity with unique mechanisms of action. Using chemosynthesis and biosynthesis strategies, it is possible to bring these antiviral natural products into further clinical development. Additionally, a multidisciplinary method that comprised of genomics, metabolomics, microbiology, natural products chemistry, and pharmacology may enrich the pipeline of novel antiviral drugs development with potential lead compounds, which will conduct to a worldwide search for clinically antivirus molecules.

### Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

### Acknowledgments

This research was funded by the National Natural Science Foundation of China (41706167), National 111 Project of China (D16013), and Li Dak Sum Yip Yio Chin Kenneth Li Marine Bio-pharmaceutical Development Fund.

### References

[1] M. Akram, I.M. Tahir, S.M.A. Shah, Z. Mahmood, A. Altaf, K. Ahmad, N. Munir, M. Daniyal, S. Nasir, H. Mehbboob, Antiviral potential of medicinal plants against HIV, HSV, influenza, hepatitis, and coxsackievirus: a systematic review, Phytother Res. 32 (2018) 811–822.
[2] E.J. Chow, J.D. Doyle, T.M. Uyeki, Influenza virus-related critical illness: prevention, diagnosis, treatment, Crit. Care 23 (2019) 214.
[3] X. Xu, Y. Zhang, Q. Li, Characteristics of herpes simplex virus infection and pathogenesis suggest a strategy for vaccine development, Rev. Med. Virol. 29 (2019), e2054.
[4] J. Rodriguez-Munoz, S. Moreno, Strategies for the cure of HIV infection, Enferm. Infecc. Microbiol. Clin. 37 (2019) 265–273.
[5] E. Priante, M,E. Cavichchiolo, E. Baraldi, RSV infection and respiratory sequelae, Minerva Pediatr. 70 (2018) 623–633.
[6] Y. Jin, R. Zhang, W. Wu, G. Duan, Antiviral and inflammatory cellular signaling associated with enterovirus 71 infection, Viruses 10 (2018) 155.
[7] N. Uno, T.M. Ross, Dengue virus and the host innate immune response, Emerg. Microb. Infect. 7 (2018) 167.
[8] T. Hoenen, A. Groseth, H. Feldmann, Therapeutic strategies to target the Ebola virus life cycle, Nat. Rev. Microbiol. 17 (2019) 593–606.
[9] X. Cao, COVID-19: immunopathology and its implications for therapy, Nat. Rev. Immunol. 20 (2020) 269–270.
[10] C.J. Neiderud, How urbanization affects the epidemiology of emerging infectious diseases, Infect. Ecol. Epidemiol. 5 (2015) 27060.

[11] L. Strasfeld, S. Choudhuri, Antiviral drug resistance: mechanisms and clinical implications, Infect. Dis. Clin. North Am. (2020) 809–833.

[12] J. Han, J. Perez, A. Schafer, Influenza virus: small molecule therapeutics and mechanisms of antiviral resistance, Curr. Med. Chem. 25 (2018) 5115–5127.

[13] J.X. Zhang, Validating entry inhibitors as an antiviral drug target and the discovery of telaprevir as a potent D68-2Apro inhibitor, J. Virol. 93 (2019), e02221.

[14] M. Novikova, Y. Zhang, E.O. Freed, K. Peng, Multiple roles of HIV-1 capsid during the virus entry cycle, Viril. Sin. 34 (2019) 119–134.

[15] E.D. Cerqu, ASPET koryo award lecture, molecular targets for antiviral agents, J. Pharmacol. Exp. Therapeut. 297 (2001) 1–10.

[16] S.M. Schneider, S.M. Pritchard, G.A. Wuduri, C.E. Trammell, A.V. Nicola, Early steps in Herpes Simplex Virus infection blocked by a proteasome inhibitor, mBio 10 (2019), e00732.

[17] J.C. Yombi, H. Mertes, Treatment as prevention for HIV infection: current data, recent advances and future perspectives, AIDS Rev. 20 (2018) 131–140.

[18] I.T.C. Silveira, B. Tura, M. Santos, Systematic review of dengue vaccine efficacy, BMC Infect. Dis. 19 (2019) 750.

[19] J.W. Blunt, A.R. Carroll, B.R. Copp, R.A. Davis, R.A. Keyzers, M.R. Prinsep, Marine derived compounds and their antiviral activities, Curr. Med. Chem. 27 (2017) 5115–5706.

[20] P. Wang, L. Xi, P. Liu, Y. Wang, W. Wang, Y. Huang, W. Zhu, Diketopiperazine from the gorgonian-derived fungus Cladosporium sp. OUCMDZ-1492, MedChemComm 5 (2014) 472.

[21] F. Kong, C. Zhao, J. Hao, C. Wang, W. Huang, W. Zhu, New α-glucoisidase inhibitors from a marine sponge-derived fungus, Aspergillus sp. OUCMDZ-1583, RSC Adv. 5 (2015) 88852–88863.

[22] J. Fan, Y. Wang, P. Liu, P. Fu, T. Zhu, W. Wang, W. Zhu, Indole-diterpenoids with anti-HIV-1 activity from the mangrove fungus Penicillium camemberti OCMDZ-1492, J. Nat. Prod. 76 (2013) 1328–1336.

[23] F. He, J. Bao, X. Zhang, Z. Tu, Y. Shi, S. Qi, Asperterestride A, a cytotoxic cyclic tetrapeptide from the marine-derived fungus Aspergillus terreus derived fungus Aspergillus ochraceus jfma1F17, MedChemComm 5 (2014) 1336–1338.

[24] W. Fang, X. Lin, J. Wang, R. Liang, Y. Tian, L. Salendra, Z. Fu, Three highly oxygenated sterols and one new dihydroisocoumarin from the marine-derived sponge fungus Cladosporium sp. SC5041007, Steroids 129 (2018) 56–68.

[25] G. Lodi, S. Petti, The controversial natural history of oral herpes simplex virus type 1 infection, Oral Dis. 25 (2019) 1850–1865.

[26] M.J. Groves, Genital herpes: a review, Am. Fam. Physician 93 (2016) 932–948.

[27] A. Sauerbrei, S. Schmitt, T. Schaper, B. Brandt, P. Wurtz, Seroprevalence of herpes simplex virus type 1 and type 2 in Thuringia, Germany, 1999 to 2006, Euro Surveil. 16 (2011), 20005.

[28] A. Birmann, H. Zimmermann, HSV antivirals - current and future treatment options, Curr. Opin. Virol. 18 (2016) 9–13.

[29] J. Piret, G. Boivin, Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management, Antimicrob. Agents Chemother. 55 (2011) 459–472.

[30] J.T. Schiffer, S.I. Gottlieb, Biologic interactions between HSV-2 and HIV-1 and possible implications for HSV vaccine development, Vaccine 37 (2019) 763–771.

[31] H. Huang, X. Song, R. Zhang, X. Wang, J. Ju, Octyl substituted butenolides from marine-derived Streptomyces koyangiensis, Nat. Prod. Res. (2019) 1–6, https://doi.org/10.1080/14786419.2018.1668368.

[32] X. Liang, X. Nong, Z. Huang, S. Qi, Antifungal and antiviral cyclic peptides from the deep-sea-derived fungus Simplicillium ochlobutum EODSF 020, J. Agric. Food Chem. 65 (2017) 5114–5121.

[33] Z. Huang, X. Nong, Z. Ren, J. Wang, X. Zhang, S. Qi, Anti-HSV-1, antioxidant and antifouling phenolic compounds from the deep-sea-derived fungus Aspergillus Persicinum SC504152, Bioorg. Med. Chem. Lett 27 (2017) 787–917.

[34] Y. Sun, J. Wang, Y. Wang, X. Zhang, X.H. Nong, M. Chen, X. Xu, S. Qi, Cytotoxic antitumor tetraacid derivatives from the deep-sea-derived fungus Tricho- botrys effusus DFFSCS01, Tetrahedron 47 (2016) 9328–9332.

[35] Z. Liu, J. Yang, Z. Ren, Q. Wang, X. Li, J. Ju, H. Huang, Natural hydroxamate-containing siderophore acrepomembranes A–D and an aluminum complex of acrepomembrane D from the marine-derived Acrepomembrana perpusilla SC504115, J. Nat. Prod. 82 (2019) 2594–2600.

[36] Z.X. Ma, X. Nong, Z. Ben, J. Wang, X. Liang, L. Wang, S. Qi, Antiviral peptides from marine gorgonian-derived fungus Aspergillus sp. SC5041501, Tetrahedron Lett. 58 (2017) 1115–1155.

[37] X. Nong, Y. Wang, X. Zhang, M. Zhou, X. Xu, S. Qi, Terriretin and butyrolactone derivatives from a marine-derived fungus Aspergillus terreus, Mar. Drugs 12 (2014) 6131–6142.

[38] M.A.M. Shushini, R. Singh, R. Mentel, U. Lindequist, Balticold: a new 12-membered macrolide with antiviral activity from an ascomycetous fungus isolated from Baltic sea origin, Mar. Drugs 14 (2016) 841–847.

[39] M.A.M. Shushini, R. Mentel, U. Lindequist, R. Jansen, Baltics A–F, new naphthalenedione derivatives with antiviral activity, from an ascomycetous fungus, Chem. Biodivers. 6 (2009) 127–137.

[40] D.S. Goodsell, Illustrations of the HIV life cycle, Curr. Top. Microbiol. Immunol. 188 (1994) 3–25.

[41] M. Yi et al. / European Journal of Medicinal Chemistry 207 (2020) 112790
1640–1646.

[72] Z. Liang, Q. Mao, F. Gao, J. Wang, Progress on the research and development of human enterovirus 71 (EV71) vaccines, Front. Med. 7 (2013) 111–121.

[73] K.X. Wu, M.M. Ng, J.J.H. Chu, Developments towards antiviral therapies against enterovirus 71, Drug Discov. Today 15 (2010) 1041–1051.

[74] S. Chen, J. Wang, Z. Wang, X. Lin, B. Zhao, K. Kaliaperumal, X. Liao, Z. Tu, J. Li, S. Xu, Y. Liu, Structurally diverse secondary metabolites from a deep-sea-derived fungus Penicillium chrysogenum SCSIO 41001 and their biological evaluation, Fitoterapia 117 (2017) 71–78.

[75] X. Pang, X. Lin, Y. Tian, R. Liang, J. Wang, B. Yang, Z. Tu, Three new polyketides from the marine sponge-derived fungus Trichoderma sp. SC3041004, Nat. Prod. Res. 32 (2018) 105–111.

[76] M.G. Guzman, E. Harris, Dengue, Lancet 385 (2015) 453–465.

[77] D. Wu, H. Li, D.R. Smith, J. Jaratsittisin, X. Xiakreer, W. Ma, D. Yang, Polyketides and alkaloids from the marine-derived fungus Dichotomomyces cepii F31-1 and the antiviral activity of scequinadoline A against dengue virus, Mar. Drugs 16 (2018) 229.

[78] D. Staveness, R. Abdelnabi, K.E. Near, Y. Nakagawa, J. Neyts, L. Delang, P. Leyssen, P.A. Wender, Inhibition of chikungunya virus-induced cell death by salicylate-derived bryostatin analogues provides additional evidence for a PKC-independent pathway, J. Nat. Prod. 79 (2016) 680–684.

[79] D.K. Gupta, P. Kaur, S.T. Leong, L.T. Tan, M.R. Prinsep, J.J. Chu, Anti-Chikungunya viral activities of aplysiatoxin-related compounds from the marine cyanobacterium Trichodesmium erythraeum, Mar. Drugs 12 (2014) 115–127.

[80] P.C. Delekta, A. Raveh, M.J. Larsen, P.J. Schultz, G. Tamayo-Castillo, D.H. Sherman, D.J. Miller, The combined use of alphavirus replicons and pseudoinfectious particles for the discovery of antivirals derived from natural products, J. Biomol. Screen 20 (2015) 673–680.

[81] A. Raveh, P.C. Delekta, C.J. Dobry, W. Peng, P.J. Schultz, P.K. Blakely, A.W. Tai, T. Matainaho, D.N. Irani, D.H. Sherman, D.J. Miller, Discovery of potent broad spectrum antivirals derived from marine actinobacteria, PloS One 8 (2013), e82318.